Based on the etiology of the tuberous sclerosis complex (TSC), which is related to mutations in oncogene suppressor TSC1 and TSC2 genes causing overactivation of mTOR, a randomized clinical trial examining Everolimus in a Study of Tuberous Sclerosis Complex (EXIST-3) was performed to evaluate the efficacy and safety of everolimus as an adjuvant treatment for seizures in TSC patients (French et al., 2016). The gene discussed is MTOR; the disease is tuberous sclerosis.